Latest news with #laboratories
BBC News
4 days ago
- Health
- BBC News
Plans for seven-storey Leicester Royal Infirmary building extension
Plans have been lodged to create a seven-storey extension to a building at Leicester Royal Infirmary (LRI). University Hospitals of Leicester NHS Trust (UHL) has submitted a planning application to Leicester City Council to construct an extension to the Windsor Building on the LRI documents stated the new space would house pharmacy services, laboratories and administrative space. According to the Local Democracy Reporting Service (LDRS), the scheme was needed to enable a wider overhaul of Leicester's three hospital sites under the government's New Hospital Programme by relocating services expected to be displaced by the wider works. The government announced in January the regeneration of Leicester's hospitals would be going ahead but on a delayed timeline, meaning work was expected to start between 2032 and 2034, the LDRS said. According to planning documents, the proposed extension was similar to a previous application submitted by the trust, which was approved but not implemented due to "funding constraints". Under the plan, the expansion would be built on the east wing of the building and a single storey building on the site would be demolished to make space for it.
Bloomberg
16-07-2025
- Business
- Bloomberg
Cerba Healthcare Bank Debt Trades Before Talks With Creditors
The sale of a piece of a Cerba Healthcare SACA bank loan signals lenders are seeking to trim their exposure to the French laboratories business before the start of debt talks. A €30 million ($35 million) portion of Cerba's revolving credit facility was sold at just below 70 cents on the euro Tuesday, according to people familiar with the matter, who asked not to be identified discussing private trades.
Associated Press
03-07-2025
- Business
- Associated Press
U.S. Independent Laboratories Pricing Database 2025: 25th Percentile, 50th Percentile, 75th Percentile, 90th Percentile Benchmarks by Each State
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'U.S. Independent Laboratories Pricing Database by State' database has been added to offering. The U.S. Independent Laboratories Pricing by State Database is a central repository for comprehensive pricing benchmarks for independent laboratories operating in the United States of America within a specified state. Pricing is collected from surveys and adjudicated claims data. The publisher uses AI and machine learning to analyze historical data and apply inflation adjustments to generated forecasted current year prices. This database contains a comprehensive overview of pricing data for independent laboratories operating in the United States of America within a specified state and all CBSAs within that specified state for the following pricing benchmarks: Intended Users: The publisher has a well-established reputation for providing industry leading pricing data for healthcare providers and the various entities that support them. This pricing data has been featured by such leading publishers as Becker's Health Review, NY Times, Wall Street Journal, Modern Healthcare, HFMA, and Kaiser Health News. Key Topics Covered: I. Overview a. Description of Specified State b. Summary of database criteria II. Database Content - Table 1 a. CBSA Code b. CBSA Name c. HCPCS Code d. HCPCS Description e. 25th Percentile Price Benchmark f. 50th Percentile Price Benchmark g. 75th Percentile Price Benchmark h. 90th Percentile Price Benchmark III. Database Content - Table 2 a. State Abbreviation b. State Name c. HCPCS Code d. HCPCS Description e. 25th Percentile Price Benchmark f. 50th Percentile Price Benchmark g. 75th Percentile Price Benchmark IV. Outputs a. .CSV b. .PDF For more information about this database visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: RESEARCH SCIENCE SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 09:45 AM/DISC: 07/03/2025 09:45 AM
Yahoo
27-06-2025
- Business
- Yahoo
Kalorama Highlights Key Trends and Breakthroughs in Blood Typing Market in New Report
ARLINGTON, Va., June 27, 2025 /PRNewswire/ -- As the world of transfusion medicine evolves, so too does the complexity and capability of blood grouping and typing technologies. In its latest In-Vitro Diagnostics Business Outlook market analysis, Kalorama Information explores the shifting landscape of blood typing—from traditional methods to cutting-edge molecular diagnostics—and what it means for laboratories, vendors, and patients alike. The new article uncovers how automation and molecular innovations are transforming how laboratories identify blood types and manage transfusion compatibility. The study highlights how automated systems are becoming essential tools in labs facing staffing shortages, offering improved efficiency and reducing the risk of human error. The report also dives into the increasing role of molecular methods in resolving complex or rare blood group discrepancies—an area gaining urgency as the population of cancer patients and those requiring transfusions continues to grow. Perhaps most excitingly, Kalorama covers the discovery of a new blood group system, the first of its kind in five decades, which may carry serious implications for transfusion safety protocols and donor compatibility standards moving forward. Key report features include: The current and projected market size for blood grouping/typing technologies through 2029. A look at regional market leaders and growth trends in North America, Europe, and Asia Pacific. An overview of leading companies such as Grifols, QuidelOrtho, Bio-Rad, and others driving innovation in immunohematology. For industry stakeholders—from hospital labs to diagnostic OEMs—this report offers strategic insights into market dynamics, product innovation, and regional opportunities that are reshaping transfusion medicine. To learn more about the report or request access, visit or contact us at info@ About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Media Contact:Name: Alisa AlvichTitle: Marketing DirectorEmail: marketing@ (703)778-3080Company: Kalorama Information, a Science and Medicine Group companyWebsite: View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-06-2025
- Politics
- Yahoo
Israeli scientists scramble to save work after Iranian missile hits labs
By Artorn Pookasook REHOVOT, Israel (Reuters) -Researchers at Israel's prestigious Weizmann Institute of Science have been scrambling to save their experiments after an Iranian missile destroyed a building containing dozens of cutting-edge laboratories. The missile struck the institute's campus at Rehovot, on the southern periphery of Tel Aviv, in the early hours of Sunday, damaging multiple buildings and prompting researchers to clamber into the ruins to save samples even as fire raged. No one was hurt as the campus was empty overnight, but one part of a building collapsed, while in the remaining part the walls were blown out, exposing a tangle of twisted metal, blasted debris and blackened cement. "We did our best to save as much of the samples as we could from the labs, from the buildings, while we were fighting the fire," physicist Roee Ozeri, Weizmann's vice president for development and communications, told Reuters. Prime Minister Benjamin Netanyahu visited the devastated site on Friday and praised the researchers as well as the rescuers of the country's emergency services, describing both groups as the "best of Israel." "This building behind me, next to me, says everything," Netanyahu said, pointing to the massive pile of rubble. "Iran is the pre-eminent terrorist regime in the world. It must not, cannot have nuclear weapons. That is the purpose of Israel's actions - to save itself from the Iranian threat of annihilation, but by doing so, we are saving many, many others.' Israel began attacking Iran on June 13, saying its longtime enemy was on the verge of developing nuclear weapons. Iran, which says its nuclear programme is only for peaceful purposes, retaliated with missile and drone attacks on Israel. Israel's strikes have killed several prominent Iranian nuclear scientists, wiped out the top echelon of Iran's military command, damaged nuclear capabilities and killed hundreds of civilians. Iran has not said if or why it targeted the Weizmann Institute. Last Thursday, the U.N. nuclear watchdog's 35-nation Board of Governors declared Iran in breach of its non-proliferation obligations for the first time in almost 20 years. Iran has long maintained its nuclear programme is for peaceful purposes. Iran's attacks have killed 24 civilians in Israel and damaged hundreds of structures, including a hospital in the southern city of Beersheba. While most of the institute's research is in areas with potential benefits for medicine and scientific knowledge, it also has connections with defence. It announced in October 2024 a collaboration with Israel's largest defence firm Elbit on "bio-inspired materials for defence applications". A multidisciplinary institution which carries out research in fields including genetics, immunology and astrophysics, Weizmann was founded in 1934 and is considered world-class within the international scientific community. It is Israel's most important science research institute, with 286 research groups, 191 staff scientists and hundreds of PhD students, master's students and postdoctoral fellows. 'EVERYTHING IS LOST' The Iranian missile hit the work of researchers such as Eldad Tzahor, who focuses on regenerative medicine with particular relevance to adult heart diseases. He said many samples and tissues that had been part of long-running experiments had been destroyed. "Everything is lost," he told Reuters TV. "I would estimate that it will take us about a year to get into a full year of research and with everything working again." In financial terms, the damage is estimated at $300-$500 million, according to the institute, which operates costly, complex machines, often shared between several labs or research groups. Jacob Hanna, who runs a molecular genetics team focused on embryonic stem cell biology, told the scientific journal Nature that his lab's ceiling had collapsed and the staircase had detached. His students managed to save hundreds of frozen mouse and human cell lines by transferring them to back-up liquid-nitrogen tanks that Hanna had stored in the basement, Nature reported. "I was always worried that if a war actually happens, I don't want to lose these," he said. (Additional reporting by Maayan Lubell and Howard Goller; Writing and additional reporting by Estelle Shirbon; Editing by Alison Williams and Alistair Bell)
